KALA BIO, Inc. — Director's Dealing 2023

Jan 7, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2023-01-04

Reporting Person: Bazemore Todd (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-01-04	Common Stock	A	12800	—	Acquired	14897	Direct
2023-01-04	Common Stock	S	62	$28.54	Disposed	14835	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1	Indirect

Footnotes

F1: Grant of restricted stock units ("RSUs") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2024, as to 1/3 of the shares underlying the RSUs on January 4, 2025 and as to the final 1/3 of shares underlying the RSUs on January 4, 2026.

F2: Includes 13,167 unvested RSUs.

F3: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units ("RSUs") granted on January 4, 2021.

F4: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.52 to $28.73, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F5: Includes 12,984 unvested RSUs.